| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1592/PHCO.31.9.896 |
| P698 | PubMed publication ID | 21923591 |
| P2093 | author name string | Evan M Sisson | |
| P2860 | cites work | Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study | Q24656600 |
| Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man | Q26776977 | ||
| Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial | Q28286240 | ||
| Correct homeostasis model assessment (HOMA) evaluation uses the computer program | Q28290512 | ||
| Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration | Q28378259 | ||
| Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide | Q33608023 | ||
| An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future. | Q33786150 | ||
| Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) | Q33854032 | ||
| Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. | Q34381400 | ||
| Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus | Q34561512 | ||
| Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study | Q34598940 | ||
| Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy | Q34616881 | ||
| Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial | Q34745045 | ||
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). | Q34986024 | ||
| Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus | Q35824086 | ||
| Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans | Q35844598 | ||
| Therapeutic strategies based on glucagon-like peptide 1. | Q35872582 | ||
| Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide. | Q36543063 | ||
| Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus | Q36715772 | ||
| Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management | Q36937820 | ||
| Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors | Q36945112 | ||
| Incretins and their role in the management of diabetes | Q36973100 | ||
| Incretin hormone mimetics and analogues in diabetes therapeutics | Q37022361 | ||
| Impact of therapeutic advances on hypoglycaemia in type 2 diabetes | Q37071750 | ||
| Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials | Q37187301 | ||
| Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). | Q37235840 | ||
| The incretin system and its role in type 2 diabetes mellitus | Q37266863 | ||
| Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial | Q37348811 | ||
| Unraveling the science of incretin biology | Q37493191 | ||
| Albiglutide: a new GLP-1 analog for the treatment of type 2 diabetes | Q37724230 | ||
| Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide? | Q37738727 | ||
| Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. | Q39732229 | ||
| Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness | Q40058795 | ||
| Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes | Q40404408 | ||
| The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. | Q40585257 | ||
| Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents | Q40718402 | ||
| GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice | Q41984767 | ||
| Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules | Q42504466 | ||
| Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase | Q42937196 | ||
| Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial | Q43086322 | ||
| Addition of incretin therapy to metformin in type 2 diabetes | Q43086326 | ||
| Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide | Q43172648 | ||
| Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue | Q43237616 | ||
| Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. | Q43279508 | ||
| Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes | Q43867550 | ||
| Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects | Q44081118 | ||
| Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects | Q44273278 | ||
| Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative | Q44468657 | ||
| One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. | Q44865459 | ||
| Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial | Q44909518 | ||
| The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes | Q44995597 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes | Q45124469 | ||
| Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial | Q46344895 | ||
| The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro | Q46409597 | ||
| Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea | Q46458866 | ||
| Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes | Q46458868 | ||
| Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test | Q46708958 | ||
| Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus | Q46804042 | ||
| Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes | Q47296454 | ||
| Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. | Q47308234 | ||
| Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes | Q47317632 | ||
| Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. | Q51015452 | ||
| DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. | Q51379684 | ||
| Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. | Q51571637 | ||
| An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide. | Q51804681 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacology | Q128406 |
| liraglutide | Q2526479 | ||
| P304 | page(s) | 896-911 | |
| P577 | publication date | 2011-09-01 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | Liraglutide: clinical pharmacology and considerations for therapy | |
| P478 | volume | 31 |
| Q44476616 | (Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and β-cell function in high-fat-fed mice |
| Q42735100 | An accidental liraglutide overdose: case report |
| Q38556037 | An update on the clinical pharmacology of the dipeptidyl peptidase 4 inhibitor alogliptin used for the treatment of type 2 diabetes mellitus |
| Q38546981 | Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus |
| Q42091122 | Liraglutide suppresses the plasma levels of active and des-acyl ghrelin independently of active glucagon-like Peptide-1 levels in mice |
| Q38804945 | Novel Insights into Structure-Activity Relationships of N-Terminally Modified PACE4 Inhibitors. |
| Q26829529 | Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus |
| Q36809901 | Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study |
| Q30357431 | The future role of gut hormones in the treatment of obesity |
Search more.